Wang J, et al. - Experts in a prospectively planned analysis of the APC trial tested the presumption that expression of target enzymes in adenomas removed before beginning study treatment would identify individuals at high risk of adenoma development, and/or predict response to Cox-2 inhibition. As per data, in pre-treatment adenomas, predictive information was provided by the expression of Cox-2 and 15-PGDH in patients treated with celecoxib for prevention of colorectal adenomas. Cox-2 and 15-PGDH were seen to be characteristics of colorectal adenomas that could be used to predict NSAID chemoprevention efficacy.